Molecule
Levetiracetam is a prescription medicine indicated for the treatment of partial-onset seizures in patients 1 month of age and older, among other approved uses. MedsAcross supplies Levetiracetam for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
KEPPRA is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. KEPPRA is indicated for adjunctive therapy for the treatment of: Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy
Source: US FDA prescribing information
The precise mechanism(s) by which levetiracetam exerts its antiepileptic effect is unknown. A saturable and stereoselective neuronal binding site in rat brain tissue has been described for levetiracetam. Experimental data indicate that this binding site is the synaptic vesicle protein SV2A, thought to be involved in the regulation of vesicle exocytosis. Although the molecular significance of levetiracetam binding to SV2A is not understood, levetiracetam and related analogs showed a rank order of affinity for SV2A which correlated with the potency of their antiseizure activity in audiogenic seizure-prone mice. These findings suggest that the interaction of levetiracetam with the SV2A protein may contribute to the antiepileptic mechanism of action of the drug.
Source: US FDA prescribing information
Use the oral solution for pediatric patients with body weight ≤ 20 kg. For pediatric patients, use weight-based dosing for the oral solution with a calibrated measuring device (not a household teaspoon or tablespoon). Partial-Onset Seizures (monotherapy or adjunctive therapy) 1 Month to < 6 Months: 7 mg/kg twice daily, increase by 7 mg/kg twice daily every 2 weeks to recommended dose of 21 mg/kg twice daily 6 Months to < 4 Years: 10 mg/kg twice daily, increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 25 mg/kg twice daily 4 Years to < 16 Years: 10 mg/kg twice daily, increase by 10 mg/kg twice daily every 2 weeks to recommended dose of 30 mg/kg twice daily. Adults 16 Years and Older: 500 mg twice daily, increase by 500 mg twice daily every 2 weeks to a recommended dose of 1500 mg twice daily.
Source: US FDA prescribing information
KEPPRA is contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema. Known hypersensitivity to levetiracetam, angioedema and anaphylaxis have occurred
Source: US FDA prescribing information
Behavioral abnormalities including psychotic symptoms, suicidal ideation, irritability, and aggressive behavior have been observed, monitor patients for psychiatric signs and symptoms. Suicidal Behavior and Ideation: Monitor patients for new or worsening depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior. Monitor for somnolence and fatigue and advise patients not to drive or operate machinery until they have gained sufficient experience on KEPPRA. Serious Dermatological Reactions: Discontinue KEPPRA at the first sign of rash unless clearly not drug related. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity: Discontinue if no alternative etiology. Coordination Difficulties: Monitor for ataxia, abnormal gait, and incoordination.
Source: US FDA prescribing information
The following adverse reactions are discussed in more details in other sections of labeling: Behavior Abnormalities and Psychotic Symptoms Suicidal Behavior and Ideation Somnolence and Fatigue Anaphylaxis and Angioedema Serious Dermatological Reactions Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Coordination Difficulties Hematologic Abnormalities Increase in Blood Pressure Most common adverse reactions (incidence ≥ 5% more than placebo) include: Adult patients: somnolence, asthenia, infection and dizziness. Pediatric patients: fatigue, aggression, nasal congestion, decreased appetite, and irritability
Source: US FDA prescribing information
Store at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
30 presentations of Levetiracetam, sorted by availability.
6 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Levetiracetam in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 30 presentations of Levetiracetam and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 6 brand names for Levetiracetam, including Elepsia XR 1000 MG, Elepsia XR 1500 MG, Keppra, Keppra XR, Roweepra, Spritam.
Yes. The US FDA first approved Levetiracetam on 30 November 1999, according to Drugs@FDA.
Yes. Levetiracetam has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
No listed presentation of Levetiracetam is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Levetiracetam is classified under ATC code N03AX14 (Levetiracetam).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.